Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
about
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvantMultiple roles of toll-like receptor 4 in colorectal cancerEffect of vaccine administration modality on immunogenicity and efficacy.Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic.A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant.Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge.Natural phosphoryl and acyl variants of lipid A from Neisseria meningitidis strain 89I differentially induce tumor necrosis factor-alpha in human monocytesSelective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A.Rationally Designed TLR4 Ligands for Vaccine Adjuvant DiscoveryChemical synthesis and proinflammatory responses of monophosphoryl lipid A adjuvant candidates.Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.Th17 cytokines and vaccine-induced immunity.PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model.Dendritic Cell Dysfunction in Patients with End-stage Renal DiseaseHPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cellsCarrageenan as an adjuvant to enhance peptide-based vaccine potencyCharacterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvantsIntranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.TLR-based immune adjuvants.Novel drugs targeting Toll-like receptors for antiviral therapy.Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection.Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity.Preparation and immunological studies of protein conjugates of N -acylneuraminic acids.Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 yearsMyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4.Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF.Reorienting our view of particle-based adjuvants for subunit vaccines.Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells.Antigen-specific antibody responses in B-1a and their relationship to natural immunityLipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challengesA TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responsesAgonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.Construction of monophosphoryl lipid A producing Escherichia coli mutants and comparison of immuno-stimulatory activities of their lipopolysaccharides
P2860
Q21091066-77EA633C-10E5-49FF-A251-79B8344E00B7Q27008380-7E372CE4-8995-4D21-9078-5D25CFE1668DQ27692376-286710E5-B494-4C2C-A1C7-1BF5FEFBB274Q30392924-BFCE3BE2-C4AA-4C4F-B3B3-1CA0E9F98990Q30423962-8AD74F09-B403-4544-B2D7-183D95F0EC84Q30424747-5DC18894-13C5-4723-A0C2-8E3F78D670E4Q33468766-72549674-F044-4E62-B233-487C7E61457DQ33553810-BE9352A3-3AC5-4206-B68E-7B0B4197E1C4Q33654530-D7767393-C664-4A7E-B8A7-7FC9C97FBAE2Q33714195-511A1919-3E59-4A9F-A1CE-1620ED47A016Q33768989-98CDC956-B8BD-41E7-B612-E69E98F57C88Q33792227-575E8F3B-E531-483F-AE7F-D44909CB35FDQ33795071-1C208A59-4201-439D-8A6F-2897359017D2Q33835103-F0C3D5A5-E379-4364-A0CC-CE3F6A7AB7E9Q34011491-071F1188-8D75-4864-B5A2-D880BBF353E5Q34012257-E7419FBD-B9E1-4DEC-ABF4-24B98F4F06A7Q34302085-9A876DF6-312A-4123-A7BC-5F7419010E0CQ34309830-C60B3FE9-2CA0-4D15-9EFE-7489AFC0D129Q34400322-FAD5AB1F-7A79-4B43-8D60-B4873A6AEDB1Q34999938-D9872154-8F9C-4903-B422-030AC43C41D1Q35008279-DCC0C50B-6979-475D-9557-7BD9CE3E8FEEQ35059006-B878EEC6-F390-4C14-BCA9-1BBDA1AA618CQ35228550-5568096B-2511-45B6-BB0E-C5A1BB715236Q35234194-F916B4F7-F58E-4C6D-8BB1-50398086EB98Q35577825-6C255487-E700-4D44-9B46-C55BACFBD40EQ35644967-2F556319-F7B9-4D64-AC62-84C0A887DDC3Q35664854-4462DD79-F799-4C02-8F10-319F7C706AADQ35695840-86B37871-D090-4395-9BCE-E5020B7B618BQ35709212-6B0DB9AF-2D5E-43C1-87B5-4F2BEB7545C9Q35849930-3FBF4D54-30AD-4261-AD63-BC51AEA29A64Q35887152-BEA15860-8DD3-48FD-BD7E-6BA9FDA6D65BQ35946895-00330D42-888F-44D4-A26E-855CD4A13227Q35951545-45E1E4F4-F01E-4DC5-8825-A1D293093301Q35990046-777D5B81-640F-47D0-BEC9-9DE12CED7B83Q36313996-F21D52F7-5645-4A47-9E37-6B85A4442286Q36373370-B78CCF00-36DA-42DC-A0AC-DC744C4CCA9DQ36445502-058F6209-D3A9-41B0-8815-709183008778Q36465489-7B20B429-FB8F-4A2C-94D6-64CD834B1549Q36689005-F6CDDA1B-645E-41F5-9E46-7D2F25CD04B1Q36806692-1440D285-9399-471C-BE26-C7DCFB96BB3F
P2860
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
@ast
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
@en
type
label
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
@ast
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
@en
prefLabel
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
@ast
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
@en
P2093
P2860
P356
P1476
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529
@en
P2093
Christopher W Cluff
David A Johnson
David H Persing
Jory R Baldridge
Michael J Lacy
P2860
P304
P356
10.1586/14760584.2.2.219
P50
P577
2003-04-01T00:00:00Z